Skip to main content
Top
Published in: Current Treatment Options in Oncology 1/2024

03-01-2024 | Vulvar Cancer

Sentinel Lymph Node Evaluation in Early-Stage Vulvar Cancer

Authors: Courtney A. Penn, MD, Mali K. Schneiter, DO, MBA, Catherine H. Watson, MD

Published in: Current Treatment Options in Oncology | Issue 1/2024

Login to get access

Opinion Statement

Sentinel lymph node mapping (SLNM) and dissection (SLND) should be used as an alternative to full inguinofemoral lymph node dissection (IFLND) in select patients with early-stage vulvar cancer. IFLND is associated with high postoperative complications such as wound breakdown, lymphedema, lymphocyst formation, and infection. SLND in select patients offers a safe, effective, and less morbid alternative. Candidates for SLND include patients with a unifocal vulvar tumor less than four centimeters, clinically negative lymph nodes, and no prior inguinofemoral surgeries. SLND should ideally be performed by a high-volume SLN surgeon. Most commonly, SLND is performed using both radiocolloid lymphoscintigraphy (e.g., Technetium-99) and a visual tracer such as blue dye; however, near infrared imaging with indocyanine green injection is becoming more widely adopted. Further prospective studies are needed to examine the safety and efficacy of various techniques for SLND. SLND has been demonstrated to be cost-effective, especially when including perioperative complications. Further studies are needed to demonstrate quality of life differences between IFLND and SLND.
Literature
1.
go back to reference Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed
2.
go back to reference Bray F, Laversanne M, Weiderpass E, Arbyn M. Geographic and temporal variations in the incidence of vulvar and vaginal cancers. Int J Cancer. 2020;147(10):2764–71.CrossRefPubMed Bray F, Laversanne M, Weiderpass E, Arbyn M. Geographic and temporal variations in the incidence of vulvar and vaginal cancers. Int J Cancer. 2020;147(10):2764–71.CrossRefPubMed
3.
go back to reference de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.CrossRefPubMedPubMedCentral de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.CrossRefPubMedPubMedCentral
4.
go back to reference Farias-Eisner R, Cirisano FD, Grouse D, Leuchter RS, Karlan BY, Lagasse LD, et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1–2N0-1M0) disease. Gynecol Oncol. 1994;53(1):55–8.CrossRefPubMed Farias-Eisner R, Cirisano FD, Grouse D, Leuchter RS, Karlan BY, Lagasse LD, et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1–2N0-1M0) disease. Gynecol Oncol. 1994;53(1):55–8.CrossRefPubMed
5.
go back to reference Network NCC. NCCN Clinical Practice Guidelines in Oncology for Vulvar Cancer. NCCN; 2024. Network NCC. NCCN Clinical Practice Guidelines in Oncology for Vulvar Cancer. NCCN; 2024.
6.••
go back to reference Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26(6):884–9 This article is of outstanding importance as it is the first of two landmark trials demonstratinng the safety and efficacy of sentinel lymph node dissection iin select patients with early vulvar cancer.CrossRefPubMed Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26(6):884–9 This article is of outstanding importance as it is the first of two landmark trials demonstratinng the safety and efficacy of sentinel lymph node dissection iin select patients with early vulvar cancer.CrossRefPubMed
7.
go back to reference Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Hu JC, et al. Utilization and outcomes of sentinel lymph node biopsy for vulvar cancer. Obstet Gynecol. 2016;128(4):754–60.CrossRefPubMedPubMedCentral Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Hu JC, et al. Utilization and outcomes of sentinel lymph node biopsy for vulvar cancer. Obstet Gynecol. 2016;128(4):754–60.CrossRefPubMedPubMedCentral
8.
go back to reference McCann GA, Cohn DE, Jewell EL, Havrilesky LJ. Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. Gynecol Oncol. 2015;136(2):300–4.CrossRefPubMed McCann GA, Cohn DE, Jewell EL, Havrilesky LJ. Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. Gynecol Oncol. 2015;136(2):300–4.CrossRefPubMed
9.
go back to reference •• Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012;30(31):3786-91. This article is of outstanding importance as it is the second of two landmark trials demonstratinng the safety and efficacy of sentinel lymph node dissection iin select patients with early vulvar cancer. •• Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012;30(31):3786-91. This article is of outstanding importance as it is the second of two landmark trials demonstratinng the safety and efficacy of sentinel lymph node dissection iin select patients with early vulvar cancer.
10.
go back to reference Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, et al. Outcome after sentinel lymph node dissection in vulvar cancer: a subgroup analysis of the AGO-CaRE-1 study. Ann Surg Oncol. 2017;24(5):1314–21.CrossRefPubMed Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, et al. Outcome after sentinel lymph node dissection in vulvar cancer: a subgroup analysis of the AGO-CaRE-1 study. Ann Surg Oncol. 2017;24(5):1314–21.CrossRefPubMed
11.
go back to reference Covens A, Vella ET, Kennedy EB, Reade CJ, Jimenez W, Le T. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecol Oncol. 2015;137(2):351–61.CrossRefPubMed Covens A, Vella ET, Kennedy EB, Reade CJ, Jimenez W, Le T. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecol Oncol. 2015;137(2):351–61.CrossRefPubMed
12.
go back to reference Oonk MH, van Os MA, de Bock GH, de Hullu JA, Ansink AC, van der Zee AG. A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol Oncol. 2009;113(3):301–5.CrossRefPubMed Oonk MH, van Os MA, de Bock GH, de Hullu JA, Ansink AC, van der Zee AG. A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol Oncol. 2009;113(3):301–5.CrossRefPubMed
13.
go back to reference Erickson BK, Divine LM, Leath CA, Straughn JM. Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer. Int J Gynecol Cancer. 2014;24(8):1480–5.CrossRefPubMedPubMedCentral Erickson BK, Divine LM, Leath CA, Straughn JM. Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer. Int J Gynecol Cancer. 2014;24(8):1480–5.CrossRefPubMedPubMedCentral
14.
go back to reference de Hullu JA, Hollema H, Piers DA, Verheijen RH, van Diest PJ, Mourits MJ, et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol. 2000;18(15):2811–6.CrossRefPubMed de Hullu JA, Hollema H, Piers DA, Verheijen RH, van Diest PJ, Mourits MJ, et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol. 2000;18(15):2811–6.CrossRefPubMed
15.
go back to reference Crane LM, Themelis G, Arts HJ, Buddingh KT, Brouwers AH, Ntziachristos V, et al. Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol Oncol. 2011;120(2):291–5.CrossRefPubMed Crane LM, Themelis G, Arts HJ, Buddingh KT, Brouwers AH, Ntziachristos V, et al. Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol Oncol. 2011;120(2):291–5.CrossRefPubMed
16.
go back to reference • Schaafsma BE, Verbeek FP, Peters AA, van der Vorst JR, de Kroon CD, van Poelgeest MI, et al. Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers. BJOG. 2013;120(6):758-64. This article is of importance as it demonstrates the potential use of a new way to potentially trace vulvar sentinel lymph nodes. • Schaafsma BE, Verbeek FP, Peters AA, van der Vorst JR, de Kroon CD, van Poelgeest MI, et al. Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers. BJOG. 2013;120(6):758-64. This article is of importance as it demonstrates the potential use of a new way to potentially trace vulvar sentinel lymph nodes.
17.
go back to reference Hutteman M, van der Vorst JR, Gaarenstroom KN, Peters AA, Mieog JS, Schaafsma BE, et al. Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. Am J Obstet Gynecol. 2012;206(1):89.e1-5.CrossRefPubMed Hutteman M, van der Vorst JR, Gaarenstroom KN, Peters AA, Mieog JS, Schaafsma BE, et al. Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. Am J Obstet Gynecol. 2012;206(1):89.e1-5.CrossRefPubMed
18.
go back to reference Mathéron HM, van den Berg NS, Brouwer OR, Kleinjan GH, van Driel WJ, Trum JW, et al. Multimodal surgical guidance towards the sentinel node in vulvar cancer. Gynecol Oncol. 2013;131(3):720–5.CrossRefPubMed Mathéron HM, van den Berg NS, Brouwer OR, Kleinjan GH, van Driel WJ, Trum JW, et al. Multimodal surgical guidance towards the sentinel node in vulvar cancer. Gynecol Oncol. 2013;131(3):720–5.CrossRefPubMed
19.
go back to reference • Verbeek FP, Tummers QR, Rietbergen DD, Peters AA, Schaafsma BE, van de Velde CJ, et al. Sentinel lymph node biopsy in vulvar cancer using combined radioactive and fluorescence guidance. Int J Gynecol Cancer. 2015;25(6):1086-93. This article is of importance as it outlines the common techniques used to detect sentinel lymph nodes ini early stage vulvar cancer. • Verbeek FP, Tummers QR, Rietbergen DD, Peters AA, Schaafsma BE, van de Velde CJ, et al. Sentinel lymph node biopsy in vulvar cancer using combined radioactive and fluorescence guidance. Int J Gynecol Cancer. 2015;25(6):1086-93. This article is of importance as it outlines the common techniques used to detect sentinel lymph nodes ini early stage vulvar cancer.
Metadata
Title
Sentinel Lymph Node Evaluation in Early-Stage Vulvar Cancer
Authors
Courtney A. Penn, MD
Mali K. Schneiter, DO, MBA
Catherine H. Watson, MD
Publication date
03-01-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 1/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01165-1

Other articles of this Issue 1/2024

Current Treatment Options in Oncology 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine